Study of the Administration of a Food Supplement in Patients With

Status Completed

Clinical Trial Summary

The extracorporeal shock wave lithotripsy (ESWL) is the treatment of choice for most stones in any of their locations. It is about breaking the stone without surgically intervening on the patient and getting him to expel the fragments himself. It is thought that additional treatments to the ESWL could improve the success rate of ESWL for less favorable stones. The components of our authorized food supplement have shown an inhibitory effect in vitro on the growth of calcium oxalate monohydrate crystals, even in hightly supersaturared solutions. Also these components show an inhibitory effect on the growth of calcium phosphate crystals. To sum up, it reduces the formation, inhibits the growth and promotes the dissolution of calcium oxalate and calcium phosphate kidney stones. This is the reason why this experimental study aims to modify the size limit of the stones in the ESWL with adjuvant food supplement.

Clinical Trial Description

The study treatment will be administered for 10 weeks. First, one dose will be administered every 12 hours for each patient during the 4 weeks prior to ESWL. After ESWL, and for 6 weeks, one dose will be administered every 24 hours. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05525130
Study type	Interventional
Source	Arafarma Group, S.A.
Contact
Status	Completed
Phase	N/A
Start date	April 22, 2020
Completion date	October 5, 2022

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04746378` - PRedictive Accuracy of Initial Stone Burden Evaluation.
Recruiting	`NCT05100017` - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure	N/A
Recruiting	`NCT03692715` - Antibiotic Prophylaxis Before Shock Wave Lithotripsy	Phase 4
Completed	`NCT02547805` - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days	Phase 2
Completed	`NCT02289755` - Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria	Phase 2
Completed	`NCT01690039` - Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis
Completed	`NCT01650935` - Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria	N/A
Completed	`NCT01295879` - Vitamin D Repletion in Stone Formers With Hypercalciuria	Phase 4
Recruiting	`NCT05014178` - Kidney Sodium Functional Imaging
Not yet recruiting	`NCT06199102` - The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants.	N/A
Recruiting	`NCT04374188` - Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy	N/A
Recruiting	`NCT04367155` - Efficacy of Tranexamic Acid on Blood Loss During Percutaneous Nephrolithotomy.	N/A
Recruiting	`NCT05701098` - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)	N/A
Recruiting	`NCT04389853` - Mini-PNCL vs fURS in Management of Nephrolithiasis	N/A
Completed	`NCT03348228` - Effect of Hydroxycitrate on Urine Chemistry	N/A
Completed	`NCT05350423` - Trial Assessing Renal Damage During Ureteroscopy	N/A
Completed	`NCT03454139` - Subcostal TAP Block For Percutaneous Nephrolithotomy	N/A
Recruiting	`NCT02279927` - Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy	N/A
Completed	`NCT02276924` - Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors	N/A
Completed	`NCT00159393` - Percutaneous Nephrolithotomy: A Registry and Database

Study of the Administration of a Food Supplement in Patients With Lithiasis Treated With Extracorporeal Shock Wave Lithotripsy. — FAGOTRICIA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms